Vertex Offering Up To $220M

Xconomy Boston — 

Vertex Pharmaceuticals (NASDAQ: VRTX) announced that the underwriters of its stock offering have exercised their option to purchase 1.1 million additional shares, bringing the overall size of the deal to 8.6 million shares worth a total of $220.0 million. The Cambridge, MA-based developer of the hepatitis C drug telaprevir last week priced 7.5 million shares at $25.50 apiece, for a total of $191.3 million.